Trial Profile
Brain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Diagnostic use
- 26 Jul 2016 New trial record